Breaking News Instant updates and real-time market news.

MESO

Mesoblast

$4.80

-0.08 (-1.64%)

06:11
03/25/19
03/25
06:11
03/25/19
06:11

Mesoblast licensee files for marketing approval of TEMCELL

Mesoblast announced its licensee in Japan, JCR Pharmaceuticals Co., has filed to extend marketing approval of TEMCELL for use in patients with Epidermolysis Bullosa. TEMCELL is already approved for the treatment of acute graft versus host disease, and was the first allogeneic cellular medicine to receive full regulatory approval in Japan. The parties have amended their License Agreement in order for JCR to access Mesoblast's mesenchymal stem cell wound healing patents to enable it to develop and commercialize TEMCELL for EB. Mesoblast will receive royalties on TEMCELL product sales for EB. JCR has received Orphan Designation for TEMCELL in the treatment of EB based on promising results from an investigator-initiated trial at Osaka University Hospital where TEMCELL was subcutaneously administered. JCR also intends to seek a label extension for TEMCELL in Japan for intravenous delivery of TEMCELL. Mesoblast will have access to clinical data generated by JCR in Japan to support development and commercialization of its MSC product candidate remestemcel-L in markets outside Japan for EB and other wound healing applications. Mesoblast plans to file for United States FDA regulatory approval of remestemcel-L shortly for the treatment of aGVHD.

MESO Mesoblast
$4.80

-0.08 (-1.64%)

06/07/18
HCWC
06/07/18
INITIATION
Target $17
HCWC
Buy
Mesoblast initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert started Mesoblast with a Buy rating and $17 price target. The analyst sees Mesoblast as having the strongest pipeline in the regenerative medicine space.
07/18/18
MAXM
07/18/18
NO CHANGE
Target $16
MAXM
Buy
Mesoblast price target raised to $16 at Maxim on Tasly deal in China
Maxim analyst Jason McCarthy raised his price target on Mesoblast to $16 from $14 and kept his Buy rating. The analyst cites the company's announced partnership with Tasly Pharma in China for development of MPC-150-IM in chronic heart failure and MPC-25-IC in acute myocardial infarction, adding that market into his model. McCarthy further points to Mesoblast's improved balance sheet as a result of this "great" partnership.
01/31/19
HCWC
01/31/19
INITIATION
Target $6.5
HCWC
Buy
Mesoblast assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Mesoblast with a Buy rating and $6.50 price target. The company's proprietary platform has been validated by two commercial cellular therapy products, TEMCELL and Alofisel, which were approved in Japan in 2015 for the treatment of acute Graft Versus Host Disease, and in Europe in 2018 for the treatment of perianal fistula, Ramakanth tells investors in a research note. Further, he calls Mesoblast's product pipeline "mature" with seven product candidates targeting ten indications.

TODAY'S FREE FLY STORIES

DASTY

Dassault Systemes

$0.00

(0.00%)

17:24
12/05/19
12/05
17:24
12/05/19
17:24
Initiation
Dassault Systemes initiated  »

Dassault Systemes resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ULTA

Ulta Beauty

$236.09

-3.27 (-1.37%)

17:24
12/05/19
12/05
17:24
12/05/19
17:24
Hot Stocks
Ulta Beauty up 10% to $259.20 after Q3 profit beat estimates »

The company also narrowed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

AUMN

Golden Minerals

$0.30

0.0089 (3.07%)

17:21
12/05/19
12/05
17:21
12/05/19
17:21
Syndicate
Breaking Syndicate news story on Golden Minerals »

Golden Minerals files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YEXT

Yext

$16.62

0.065 (0.39%)

17:18
12/05/19
12/05
17:18
12/05/19
17:18
Hot Stocks
Breaking Hot Stocks news story on Yext »

Yext down 21% to $13.00…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

FIZZ

National Beverage

$48.28

-1.16 (-2.35%)

17:16
12/05/19
12/05
17:16
12/05/19
17:16
Earnings
National Beverage reports Q2 EPS 70c, consensus 68c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXSM

Axsome Therapeutics

$43.27

-4.17 (-8.79%)

17:16
12/05/19
12/05
17:16
12/05/19
17:16
Syndicate
Breaking Syndicate news story on Axsome Therapeutics »

Axsome Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTHT

Huazhu Group

$34.49

1.58 (4.80%)

17:15
12/05/19
12/05
17:15
12/05/19
17:15
Upgrade
Huazhu Group rating change  »

Huazhu Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONDS

Ondas Holdings

$0.00

(0.00%)

17:12
12/05/19
12/05
17:12
12/05/19
17:12
Syndicate
Breaking Syndicate news story on Ondas Holdings »

Ondas Holdings files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GH

Guardant Health

$73.57

-1.43 (-1.91%)

17:11
12/05/19
12/05
17:11
12/05/19
17:11
Hot Stocks
Guardant Health Chief Medical Officer Richard Lanman to retire »

On December 2, Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DEI

Douglas Emmett

$44.13

0.1 (0.23%)

17:10
12/05/19
12/05
17:10
12/05/19
17:10
Hot Stocks
Douglas Emmett raises quarterly dividend by 8% to 28c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXSM

Axsome Therapeutics

$43.27

-4.17 (-8.79%)

17:06
12/05/19
12/05
17:06
12/05/19
17:06
Syndicate
Breaking Syndicate news story on Axsome Therapeutics »

Axsome Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZM

Zoom Video

$69.73

-0.22 (-0.31%)

17:06
12/05/19
12/05
17:06
12/05/19
17:06
Periodicals
Zoom Video shares fall on moderating revenue growth, CNBC reports »

Zoom's revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 16

    Dec

TRIP

TripAdvisor

$29.04

0.51 (1.79%)

, EIGI

Endurance

$4.04

-0.06 (-1.46%)

17:03
12/05/19
12/05
17:03
12/05/19
17:03
Hot Stocks
TripAdvisor acquires SinglePlatform from Endurance, terms not disclosed »

TripAdvisor (TRIP)…

TRIP

TripAdvisor

$29.04

0.51 (1.79%)

EIGI

Endurance

$4.04

-0.06 (-1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BP

BP

$36.63

-0.45 (-1.21%)

, COP

ConocoPhillips

$59.83

-0.8 (-1.32%)

16:56
12/05/19
12/05
16:56
12/05/19
16:56
Periodicals
OPEC cancels customary press conference after meeting, CNBC reports »

Amid reports that OPEC…

BP

BP

$36.63

-0.45 (-1.21%)

COP

ConocoPhillips

$59.83

-0.8 (-1.32%)

TOT

Total

$52.29

0.02 (0.04%)

XOM

Exxon Mobil

$68.41

-0.24 (-0.35%)

CVX

Chevron

$116.30

-0.66 (-0.56%)

RDS.A

Royal Dutch Shell

$56.50

-0.34 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$60.11

-89.11 (-59.72%)

16:53
12/05/19
12/05
16:53
12/05/19
16:53
Recommendations
Sage Therapeutics analyst commentary  »

Sage Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMN

Eastman Chemical

$75.68

0.67 (0.89%)

16:43
12/05/19
12/05
16:43
12/05/19
16:43
Hot Stocks
Eastman Chemical raises quarterly dividend 6.5% to 66c from 62c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRI

Everi Holdings

$11.86

-1 (-7.78%)

16:43
12/05/19
12/05
16:43
12/05/19
16:43
Syndicate
Everi Holdings 10M share Secondary priced at $11.25 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

ZUMZ

Zumiez

$30.63

0.67 (2.24%)

16:39
12/05/19
12/05
16:39
12/05/19
16:39
Earnings
Zumiez raises FY19 SSS growth view to 4.0%-4.5% from prior view 2.0%-4.0% »

Based upon better than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

CRWD

Crowdstrike

$53.00

-2.04 (-3.71%)

16:38
12/05/19
12/05
16:38
12/05/19
16:38
Earnings
Crowdstrike raises FY20 EPS view to (53c)-(52c) from (65c)-(62c) »

Consensus (63c). Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 12

    Dec

FNHC

Federated National

$15.37

-0.04 (-0.26%)

16:36
12/05/19
12/05
16:36
12/05/19
16:36
Hot Stocks
Federated National announces new $10M share repurchase program »

Federated National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWD

Crowdstrike

$53.00

-2.04 (-3.71%)

16:36
12/05/19
12/05
16:36
12/05/19
16:36
Earnings
Crowdstrike sees Q4 adjusted EPS (9c)-(8c), consensus (11c) »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 12

    Dec

CRWD

Crowdstrike

$53.00

-2.04 (-3.71%)

16:35
12/05/19
12/05
16:35
12/05/19
16:35
Earnings
Crowdstrike reports Q3 adjusted EPS (7c), consensus (11c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 12

    Dec

EPZM

Epizyme

$15.32

-0.48 (-3.04%)

16:35
12/05/19
12/05
16:35
12/05/19
16:35
Upgrade
Epizyme rating change  »

Epizyme upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

ESTA

Establishment Labs

$24.31

0.32 (1.33%)

16:35
12/05/19
12/05
16:35
12/05/19
16:35
Hot Stocks
Establishment Labs reaches one million Motiva implants milestone »

Establishment Labs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDT

IDT Corp

$7.47

0.26 (3.61%)

16:34
12/05/19
12/05
16:34
12/05/19
16:34
Earnings
IDT Corp reports Q1 EPS 10c vs. (2c) last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.